Genetics in reproductive medicine. What is the value of aneuploidy screening?

被引：0

作者：

Strowitzki T. ^{[1
,2
]}

机构：

[1] Abteilung Gynäkologische Endokrinologie und Fertilitätsstö rungen, Frauenklinik, Universitätsklinikum Heidelberg

[2] Abteilung Gynäkologische Endokrinologie und Fertilitätsstö rungen, Frauenklinik, Universitätsklinikum Heidelberg, 69115 Heidelberg

来源：

Gynäkologische Endokrinologie | 2005年 / 3卷 / 4期

关键词：

Aneuploidy screening; Gene technique; IVF; Preimplantation genetic diagnosis; Reproductive medicine;

D O I：

10.1007/s10304-005-0121-x

中图分类号：

学科分类号：

摘要：

Preimplantation genetic diagnosis-aneuploidy screening (PGD-AS) accounts for up to two thirds of PGD indications worldwide. This technique is applied in cases of advanced maternal age, repeated implantation failure after IVF, recurrent spontaneous miscarriage and for poor ovarian response. Despite more than 1,000 children born after PGD, the value of PGD-AS remains unclear. Although clinical implantation rates are increased, the overall clinical pregnancy rate does not differ from cycles without PGD, due to the low number of embryos transferred. There is no data available showing a benefit in multiple gestations. Most studies are descriptive with a paucity of controlled randomized trials. © Springer Medizin Verlag 2005.

引用

页码：231 / 237

页数：6